BioWorld

July 19, 2004

View Archived Issues

Nausea Taints ConjuChem's Diabetes Drug Phase II Trial

While DAC:GLP-1 hit its primary endpoint as a diabetes monotherapy in a Phase II trial that evaluated it in four doses, the drug's nausea and vomiting side effects sent ConjuChem's stock tumbling. (BioWorld Today) Read More

Xenogen's Second IPO Attempt Successful; Firm Raises $29.4M

Read More

Successor To Gleevec That Might Counter Resistance Enters Clinic

Read More

GTx Offers Strong Phase IIb With Prostate Cancer Stopper

Read More

Other News To Note

Read More

Correction

Read More